Excessive polypharmacy and survival in polypathological patients.

PURPOSE: The purpose of this study was to determine whether excessive polypharmacy is associated with a higher survival rate in polypathological patients. PATIENTS AND METHODS: An observational, prospective, and multicenter study was carried out on those polypathological patients admitted to the internal medicine and acute geriatrics departments between March 1 and June 30, 2011. For each patient, data concerning age, sex, comorbidity, Barthel and Lawton-Brody indexes, Pfeiffer's questionnaire, socio-familial Gijon scale, delirium, number of drugs, and number of admissions during the previous year were gathered, and the PROFUND index was calculated. Polypharmacy was defined as the use of ≥ 5 drugs and excessive polypharmacy as the use of ≥ 10. A 1-year long follow-up was carried out. A logistic regression model was performed to analyze the association of variables with excessive polypharmacy and a Cox proportional hazard model to determine the association between polypharmacy and survival. RESULTS: We included 457 polypathological patients. Mean age was 81.0 (8.8) years and 54.5% were women. The mean number of drugs used was 8.2 (3.4). Excessive polypharmacy was directly associated with heart disease [hazard ratio (HR) 2.33 95% CI 1.40-3.87; p =0.001], respiratory disease [HR 1.87 95% CI 1.13-3.09; p = 0.01], peripheral artery disease/diabetes with retinopathy and/or neuropathy [HR 2.02 95% CI 1.17-3.50; p = 0.01], and the number of admissions during the previous year [HR 1.21 96%CI 1.01-1.44; p = 0.04]. It was inversely associated with delirium [HR 0.48 95% CI 0.25-0.91; p = 0.02]. There were no statistical differences regarding the probability of 1-year survival between patients with no polypharmacy, with simple polypharmacy, and with excessive polypharmacy (0.66, 0.60, and 0.57, respectively, p = 0.12). CONCLUSIONS: A greater use of drugs may not be harmful but is also not associated with a higher probability of survival in polypathological patients.

Prevalencia del síndrome metabólico en los ancianos hospitalizados / Prevalence of metabolic syndrome in elderly patients

Objetivos. Conocer la prevalencia del síndrome metabólico (SM) según las definiciones del National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP III ) y la International Diabetes Federation (IDF) y su relación con la enfermedad cardiovascular (ECV) en los ancianos hospitalizados. Material y método. Estudio descriptivo, prospectivo realizado entre febrero y marzo del 2011. Se estudiaron 200 pacientes consecutivos hospitalizados. Se registraron las variables sociodemográficas, clínicas, bioquímicas y antecedentes personales. Resultados. La prevalencia del SM fue del 65% (NCEP-ATP III ) y 67,5% (IDF), siendo mayor en las mujeres (NCEP-ATP III = 72,8%; IDF = 73,6%), que en los varones (NCEP-ATP III = 50,7%; IDF = 56,3%). La edad media de los pacientes diagnosticados de SM según ambos criterios diagnósticos fue parecido: 84,7 años. El SM no se asoció a una mayor prevalencia de ECV. Conclusiones. El SM tiene una elevada prevalencia en los ancianos hospitalizados, siendo mayor en mujeres, tanto con los criterios NCEP-ATP III como con los de la IDF. En nuestra población el SM no se asoció a una mayor prevalencia de ECV (AU)

Objectives. To determine the prevalence of metabolic syndrome (MS) according to the definitions of the National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP III) and the International Diabetes Federation (IDF) and its relation to cardiovascular disease (CVD) in hospitalized elderly patients. Material and methods. This descriptive and prospective study (February-March 2011) included 200 consecutive patients hospitalized in a Geriatric Department. Sociodemographic, clinical and biochemical data was collected. Results. The prevalence of MS was 65% (NCEP-ATP III) and 67.5% (IDF) and was greater in women (NCEP-ATP III=72.8%, IDF=73.6%) than in men (NCEP-ATP III=50.7%; IDF=56.3%). The mean age of patients diagnosed with MS by both diagnostic criteria were similar: 84.7 years. MS was not associated with an increased prevalence of CVD. Conclusions. MS is highly prevalent in elderly hospitalized patients, being higher in women, with both diagnostic criteria (NCEP- ATP III and IDF). In our population the MS was not associated with an increased prevalence of CVD (AU)

[Prevalence of metabolic syndrome in elderly patients]. / Prevalencia del síndrome metabólico en los ancianos hospitalizados.

OBJECTIVES: To determine the prevalence of metabolic syndrome (MS) according to the definitions of the National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP III) and the International Diabetes Federation (IDF) and its relation to cardiovascular disease (CVD) in hospitalized elderly patients. MATERIAL AND METHODS: This descriptive and prospective study (February-March 2011) included 200 consecutive patients hospitalized in a Geriatric Department. Sociodemographic, clinical and biochemical data was collected. RESULTS: The prevalence of MS was 65% (NCEP-ATP III) and 67.5% (IDF) and was greater in women (NCEP-ATP III=72.8%, IDF=73.6%) than in men (NCEP-ATP III=50.7%; IDF=56.3%). The mean age of patients diagnosed with MS by both diagnostic criteria were similar: 84.7 years. MS was not associated with an increased prevalence of CVD. CONCLUSIONS: MS is highly prevalent in elderly hospitalized patients, being higher in women, with both diagnostic criteria (NCEP- ATP III and IDF). In our population the MS was not associated with an increased prevalence of CVD.